267 related articles for article (PubMed ID: 16372138)
1. [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie].
Horneff G
Z Rheumatol; 2006 Mar; 65(2):152-6, 158. PubMed ID: 16372138
[TBL] [Abstract][Full Text] [Related]
2. [Biological therapy treatment of juvenile idiopathic arthritis].
Herlin T
Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
[TBL] [Abstract][Full Text] [Related]
3. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
[TBL] [Abstract][Full Text] [Related]
4. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].
Horneff G
Z Rheumatol; 2005 Jun; 64(5):317-26. PubMed ID: 15965816
[TBL] [Abstract][Full Text] [Related]
5. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
6. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].
Horneff G
Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787
[TBL] [Abstract][Full Text] [Related]
7. [The importance of biologicals in the treatment of SoJIA].
Dückers G; Niehues T
Z Rheumatol; 2010 Aug; 69(6):505-15. PubMed ID: 20668866
[TBL] [Abstract][Full Text] [Related]
8. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
[TBL] [Abstract][Full Text] [Related]
9. Juvenile idiopathic arthritis: current and future treatment options.
Martini G; Zulian F
Expert Opin Pharmacother; 2006 Mar; 7(4):387-99. PubMed ID: 16503811
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.
Otten MH; Anink J; Spronk S; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 Nov; 72(11):1806-12. PubMed ID: 23172748
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
12. When should we use TNF antagonists in children with rheumatic disease?
Quartier P
Joint Bone Spine; 2007 Jan; 74(1):1-3. PubMed ID: 17174585
[No Abstract] [Full Text] [Related]
13. Treatment of juvenile idiopathic arthritis in the biologic age.
Stoll ML; Cron RQ
Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
[TBL] [Abstract][Full Text] [Related]
14. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
15. Trials reveal promising options for treating juvenile rheumatoid arthritis.
Hampton T
JAMA; 2008 Jan; 299(1):27-8. PubMed ID: 18167400
[No Abstract] [Full Text] [Related]
16. Juvenile idiopathic arthritis: therapies in the 21st century.
Haines KA
Bull NYU Hosp Jt Dis; 2007; 65(3):205-11. PubMed ID: 17922671
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.
Ramos-Casals M; Brito-Zerón P; Muñoz S; Soto MJ;
Medicine (Baltimore); 2008 Nov; 87(6):345-364. PubMed ID: 19011506
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy.
Strehblow C; Haberhauer G; Fasching P
Wien Med Wochenschr; 2010 May; 160(9-10):225-9. PubMed ID: 20632150
[TBL] [Abstract][Full Text] [Related]
19. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
